Condition: Tuberculosis · Acute Coronary Syndrome · Pulmonary Hypertension (Diagnosis) · Sponsor: National University Hospital, Singapore
Tuberculosis (TB) is a global pandemic that despite successful treatment and bacterial eradication can cause chronic ill health, such as pulmonary impairment after tuberculosis (PIAT) and cardiovascular disease (CVD). A recent Phase 2b double-blind randomised-controlled clinical trial shows that adjunctive doxycycline therapy is safe, accelerates resolution of inflammation, suppresses tissue damaging enzyme activity and decreases pulmonary cavity volume (1). We aim to determine if adjunctive doxycycline can reduce PIAT and improve cardiovascular outcomes in a fully powered Phase III trial of 8 weeks of adjunctive doxycycline alongside standard pulmonary TB (PTB) treatment. The investigators hypothesize that doxycycline inhibits tissue destruction in patients with PTB and thereby leads to improved lung function after treatment. Specific aims 1. To assess improvement in lung function as measured by forced expiratory volume (FEV1) predicted in PTB patients given doxycycline versus placebo. 2. To investigate whether doxycycline will hasten the resolution of pulmonary cavities measured by CT thorax 3. To investigate whether doxycycline can suppress inflammatory markers including matrix metalloproteinases 4. To investigate whether doxycycline can accelerate time to sputum conversion 5. To evaluate the effect of doxycycline on cardiovascular outcomes such as the incidence of acute coronary syndrome (ACS) and pulmonary hypertension 6. To investigate whether doxycycline improves TB…
This description comes directly from the study's public registry record.
Srishti CHHABRA, MBBS BSc MRCP · +65 6908 2222 · srishti.chhabra@mohh.com.sg
Always discuss trial participation with your own doctor first.
| Hospital Queen Elizabeth I | Kota Kinabalu, Sabah, Malaysia | Not Yet Recruiting |
| Klinik Kesihatan Luyang | Kota Kinabalu, Sabah, Malaysia | Active Not Recruiting |
| Klinik Kesihatan Menggatal | Kota Kinabalu, Sabah, Malaysia | Recruiting |
| Universiti Malaysia Sabah (UMS), Borneo Medical and Health Research Centre | Kota Kinabalu, Sabah, Malaysia | Active Not Recruiting |
| National University Hospital | Singapore, Singapore, Singapore | Recruiting |
| TB Control Unit | Singapore, Singapore | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05473520